The UK and US have forged a landmark trade agreement that will guarantee no tariffs on British drug shipments entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to raise spending on drugs through the public health system. This pledge guarantees that duties on these vital products will stay at nothing for a timeframe of three years.
This development follows earlier statements to dramatically increase import taxes on branded pharmaceutical imports, with potential rates mentioned as high as 100%.
"This arrangement with the UK bolsters the international landscape for cutting-edge drugs and introduces long-overdue balance to American-British pharmaceutical trade," an announcement declared.
Economic Importance
Pharmaceuticals are one of the Britain's biggest export categories to the US, which is by far the largest buyer for major UK drugmakers.
Trade data show that in the one-year period leading up to the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement protects employment, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official remarked.
Specific NHS Changes
The agreement includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be capped at fifteen percent. Last year, refunds topped 20%.
Industry Background
The pact follows a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American patients were paying several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
